19 June 2013
Keywords: merck, serono, expands, cilengitide, program, division, germany
Article | 23 March 2009
Merck Serono, a division of Germany's Merck KGaA, has initiated a Phase II CERTO study, which will investigate the efficacy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 March 2009
18 June 2013
© 2013 thepharmaletter.com